One Third Of Patients Who Stop Treatment For Schizophrenia Early Do So Due To Poor Response

Main Category: Schizophrenia
Article Date: 25 Dec 2005 - 0:00 PDT

email to a friend   printer friendly   opinions  

A third of patients treated for schizophrenia who stop taking their medication early do so because they do not feel any significant improvement or because their symptoms are worsening. A study published today in the open access journal BMC Medicine reveals that patients with schizophrenia are three times more likely to stop treatment because of poor response or worsening symptoms, than because of adverse non-psychiatric side effects.

Hong Liu-Seifert and colleagues from Eli Lilly and Company in Indianapolis, USA, analysed the reasons for stopping treatment of patients who took part in four previous Eli Lilly studies. The studies included a total of 1627 patients and compared the effects of taking olanzapine, risperidone, quetiapine or ziprasidone in patients diagnosed with schizophrenia or related disorders.

Liu-Seifert et al.'s analysis shows that 53% (866/1627) of patients stopped treatment early. Of the 866 patients who stopped treatment, 36% (315/866) did so because the treatment was felt not to be effective or because their symptoms worsened. Only 12% of patients who stopped treatment early did so because of adverse events such as dizziness, fatigue, vomiting or weight gain.

Of the 315 patients who stopped because of poor response to treatment, 80% stopped because they themselves believed it wasn't effective. Only 20% of the patients studied stopped taking medication based on a doctor's decision that the treatment wasn't effective.

"Discontinuation due to patient perception of poor response appeared to occur particularly early in the course of treatment," the authors write. Liu-Seifert et al. found that patients who experienced an early response to medication were 80% more likely to complete treatment.

The authors' findings suggest that early and effective symptom control, and discussing expectations of treatment, may help to ensure that people suffering from schizophrenia continue to take their medication.

BMC Medicine (www.biomedcentral.com/bmcmed) is published by BioMed Central (www.biomedcentral.com), an independent online publishing house committed to providing open access to peer-reviewed biological and medical research. This commitment is based on the view that immediate free access to research and the ability to freely archive and reuse published information is essential to the rapid and efficient communication of science.

Peer reviewed publication and references. Article:
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
Hong Liu-Seifert, David H Adams and Bruce J Kinon
BMC Medicine 2005, 3:21 (23 December 2005)

biomedcentral.com/1741-7015/3/21

BioMed Central currently publishes over 140 journals across biology and medicine. In addition to open-access original research, BioMed Central also publishes reviews, commentaries and other non-original-research content. Depending on the policies of the individual journal, this content may be open access or provided only to subscribers.

BIOMED CENTRAL LIMITED
Middlesex House,
34-42 Cleveland Street,
London,
W1T 4LB,
UK
http://www.biomedcentral.com

About BIOMED CENTRAL LIMITED

BioMed Central is an independent publishing house committed to providing immediate free access to peer-reviewed biomedical research.

• Additional
• References
• Citations